Third, lower smoking prevalence with lower tumor immunogenic landscape and higher EGFR mutation might lead to these results among women patients with lung cancer, and those female patients with EGFR tumor mutations receive no survival benefit from the immune checkpoint inhibitors. Here, EGFR is linked to lung cancer.